Literature DB >> 23894747

A comprehensive family-based replication study of schizophrenia genes.

Karolina A Aberg1, Youfang Liu, Jozsef Bukszár, Joseph L McClay, Amit N Khachane, Ole A Andreassen, Douglas Blackwood, Aiden Corvin, Srdjan Djurovic, Hugh Gurling, Roel Ophoff, Carlos N Pato, Michele T Pato, Brien Riley, Todd Webb, Kenneth Kendler, Mick O'Donovan, Nick Craddock, George Kirov, Mike Owen, Dan Rujescu, David St Clair, Thomas Werge, Christina M Hultman, Lynn E Delisi, Patrick Sullivan, Edwin J van den Oord.   

Abstract

IMPORTANCE: Schizophrenia (SCZ) is a devastating psychiatric condition. Identifying the specific genetic variants and pathways that increase susceptibility to SCZ is critical to improve disease understanding and address the urgent need for new drug targets.
OBJECTIVE: To identify SCZ susceptibility genes.
DESIGN: We integrated results from a meta-analysis of 18 genome-wide association studies (GWAS) involving 1,085,772 single-nucleotide polymorphisms (SNPs) and 6 databases that showed significant informativeness for SCZ. The 9380 most promising SNPs were then specifically genotyped in an independent family-based replication study that, after quality control, consisted of 8107 SNPs.
SETTING: Linkage meta-analysis, brain transcriptome meta-analysis, candidate gene database, OMIM, relevant mouse studies, and expression quantitative trait locus databases. PATIENTS: We included 11,185 cases and 10,768 control subjects from 6 databases and, after quality control 6298 individuals (including 3286 cases) from 1811 nuclear families. MAIN OUTCOMES AND MEASURES: Case-control status for SCZ.
RESULTS: Replication results showed a highly significant enrichment of SNPs with small P values. Of the SNPs with replication values of P.01, the proportion of SNPs that had the same direction of effects as in the GWAS meta-analysis was 89% in the combined ancestry group (sign test, P < 2.20 x 10(-16) and 93% in subjects of European ancestry only (P < 2.20 < 10(-16)). Our results supported the major histocompatibility complex region showing a3.7-fold overall enrichment of replication values of P < .01 in subjects from European ancestry. We replicated SNPs in TCF4 (P = 2.53 x 10(-10)) and NOTCH4 (P = 3.16 x 10(-7)) that are among the most robust SCZ findings. More novel findings included POM121L2 (P = 3.51 x 10(-7)), AS3MT (P = 9.01 x 10(-7)), CNNM2 (P = 6.07 = 10(-7)), and NT5C2(P = 4.09 x 10(-7)). To explore the many small effects, we performed pathway analyses. The most significant pathways involved neuronal function (axonal guidance, neuronal systems, and L1 cell adhesion molecule interaction)and the immune system (antigen processing, cell adhesion molecules relevant to T cells, and translocation to immunological synapse). CONCLUSIONS AND RELEVANCE: We replicated novel SCZ disease genes and pathogenic pathways. Better understanding the molecular and biological mechanisms involved with schizophrenia may improve disease management and may identify new drug targets.

Entities:  

Mesh:

Year:  2013        PMID: 23894747      PMCID: PMC5297889          DOI: 10.1001/jamapsychiatry.2013.288

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  42 in total

1.  Genomic analysis of mental illness: a changing landscape.

Authors:  Jon McClellan; Mary-Claire King
Journal:  JAMA       Date:  2010-06-23       Impact factor: 56.272

Review 2.  Membrane traffic: controlling membrane fusion by modifying NSF.

Authors:  Alan Morgan; Robert D Burgoyne
Journal:  Curr Biol       Date:  2004-11-23       Impact factor: 10.834

3.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

4.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.

Authors:  Nicole C Allen; Sachin Bagade; Matthew B McQueen; John P A Ioannidis; Fotini K Kavvoura; Muin J Khoury; Rudolph E Tanzi; Lars Bertram
Journal:  Nat Genet       Date:  2008-07       Impact factor: 38.330

5.  Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility.

Authors:  C O'Dushlaine; E Kenny; E Heron; G Donohoe; M Gill; D Morris; A Corvin
Journal:  Mol Psychiatry       Date:  2010-02-16       Impact factor: 15.992

6.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

Review 7.  Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance.

Authors:  Suat Ying Tan Cherlyn; Puay San Woon; Jian Jun Liu; Wei Yi Ong; Guo Chuan Tsai; Kang Sim
Journal:  Neurosci Biobehav Rev       Date:  2010-01-07       Impact factor: 8.989

8.  Genome-wide association study identifies five new schizophrenia loci.

Authors: 
Journal:  Nat Genet       Date:  2011-09-18       Impact factor: 38.330

9.  Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs.

Authors:  S Hong Lee; Teresa R DeCandia; Stephan Ripke; Jian Yang; Patrick F Sullivan; Michael E Goddard; Matthew C Keller; Peter M Visscher; Naomi R Wray
Journal:  Nat Genet       Date:  2012-02-19       Impact factor: 38.330

10.  Meta-analysis of 32 genome-wide linkage studies of schizophrenia.

Authors:  M Y M Ng; D F Levinson; S V Faraone; B K Suarez; L E DeLisi; T Arinami; B Riley; T Paunio; A E Pulver; P A Holmans; M Escamilla; D B Wildenauer; N M Williams; C Laurent; B J Mowry; L M Brzustowicz; M Maziade; P Sklar; D L Garver; G R Abecasis; B Lerer; M D Fallin; H M D Gurling; P V Gejman; E Lindholm; H W Moises; W Byerley; E M Wijsman; P Forabosco; M T Tsuang; H-G Hwu; Y Okazaki; K S Kendler; B Wormley; A Fanous; D Walsh; F A O'Neill; L Peltonen; G Nestadt; V K Lasseter; K Y Liang; G M Papadimitriou; D G Dikeos; S G Schwab; M J Owen; M C O'Donovan; N Norton; E Hare; H Raventos; H Nicolini; M Albus; W Maier; V L Nimgaonkar; L Terenius; J Mallet; M Jay; S Godard; D Nertney; M Alexander; R R Crowe; J M Silverman; A S Bassett; M-A Roy; C Mérette; C N Pato; M T Pato; J Louw Roos; Y Kohn; D Amann-Zalcenstein; G Kalsi; A McQuillin; D Curtis; J Brynjolfson; T Sigmundsson; H Petursson; A R Sanders; J Duan; E Jazin; M Myles-Worsley; M Karayiorgou; C M Lewis
Journal:  Mol Psychiatry       Date:  2008-12-30       Impact factor: 15.992

View more
  62 in total

1.  Cortical thickness and surface area in neonates at high risk for schizophrenia.

Authors:  Gang Li; Li Wang; Feng Shi; Amanda E Lyall; Mihye Ahn; Ziwen Peng; Hongtu Zhu; Weili Lin; John H Gilmore; Dinggang Shen
Journal:  Brain Struct Funct       Date:  2014-11-02       Impact factor: 3.270

2.  Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes.

Authors:  Alexis C Edwards; Tim B Bigdeli; Anna R Docherty; Silviu Bacanu; Donghyung Lee; Teresa R de Candia; Arden Moscati; Dawn L Thiselton; Brion S Maher; Brandon K Wormley; Dermot Walsh; Francis A O'Neill; Kenneth S Kendler; Brien P Riley; Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-08-27       Impact factor: 9.306

Review 3.  The Emerging Immunogenetic Architecture of Schizophrenia.

Authors:  Jennie G Pouget
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

4.  De novo FBXO11 mutations are associated with intellectual disability and behavioural anomalies.

Authors:  Daniel Fritzen; Alma Kuechler; Mona Grimmel; Jessica Becker; Sophia Peters; Marc Sturm; Hela Hundertmark; Axel Schmidt; Martina Kreiß; Tim M Strom; Dagmar Wieczorek; Tobias B Haack; Stefanie Beck-Wödl; Kirsten Cremer; Hartmut Engels
Journal:  Hum Genet       Date:  2018-05-23       Impact factor: 4.132

5.  Common variants in the MKL1 gene confer risk of schizophrenia.

Authors:  Xiong-Jian Luo; Liang Huang; Edwin J van den Oord; Karolina A Aberg; Lin Gan; Zhongming Zhao; Yong-Gang Yao
Journal:  Schizophr Bull       Date:  2014-11-07       Impact factor: 9.306

6.  Common variants on 2p16.1, 6p22.1 and 10q24.32 are associated with schizophrenia in Han Chinese population.

Authors:  H Yu; H Yan; J Li; Z Li; X Zhang; Y Ma; L Mei; C Liu; L Cai; Q Wang; F Zhang; N Iwata; M Ikeda; L Wang; T Lu; M Li; H Xu; X Wu; B Liu; J Yang; K Li; L Lv; X Ma; C Wang; L Li; F Yang; T Jiang; Y Shi; T Li; D Zhang; W Yue
Journal:  Mol Psychiatry       Date:  2016-12-06       Impact factor: 15.992

Review 7.  Schizophrenia as a disorder of molecular pathways.

Authors:  Szatmár Horváth; Károly Mirnics
Journal:  Biol Psychiatry       Date:  2014-01-10       Impact factor: 13.382

8.  Novel primate miRNAs coevolved with ancient target genes in germinal zone-specific expression patterns.

Authors:  Mary L Arcila; Marion Betizeau; Xiaolu A Cambronne; Elmer Guzman; Nathalie Doerflinger; Frantz Bouhallier; Hongjun Zhou; Bian Wu; Neha Rani; Danielle S Bassett; Ugo Borello; Cyril Huissoud; Richard H Goodman; Colette Dehay; Kenneth S Kosik
Journal:  Neuron       Date:  2014-02-27       Impact factor: 17.173

9.  Building a schizophrenia genetic network: transcription factor 4 regulates genes involved in neuronal development and schizophrenia risk.

Authors:  Hanzhang Xia; Fay M Jahr; Nak-Kyeong Kim; Linying Xie; Andrey A Shabalin; Julien Bryois; Douglas H Sweet; Mohamad M Kronfol; Preetha Palasuberniam; MaryPeace McRae; Brien P Riley; Patrick F Sullivan; Edwin J van den Oord; Joseph L McClay
Journal:  Hum Mol Genet       Date:  2018-09-15       Impact factor: 6.150

10.  Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Authors:  Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin
Journal:  Pharmacogenomics J       Date:  2015-08-18       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.